Laoung-On Jiraporn, Anuduang Artorn, Saenjum Chalermpong, Srichairatanakool Somdet, Boonyapranai Kongsak, Ounjaijean Sakaewan
Office of Research Administration, Chiang Mai University, Chiang Mai 50200, Thailand.
Research Institute for Health Sciences, Chiang Mai University, Chiang Mai 50200, Thailand.
Life (Basel). 2024 Nov 20;14(11):1515. doi: 10.3390/life14111515.
Obesity, a major global health concern, is represented by an accumulation of adipose tissue and body mass, leading to a higher incidence of non-communicable diseases (NCDs). var. , known as cha-miang, contains catechin and its derivatives, which have been reported to affect several health-related concerns such as anti-cancer, anti-inflammatory, anti-hyperlipidemia, and against cardiovascular disease. The research aimed to examine the anti-obesity and insulin resistance effects of fresh cha-miang extract (CME) and fermented cha-miang extract (FCME), and to investigate the anti-obesity and anti-diabetic effects of CME and FCME in obese rats generated by a high-fat diet. The extracts demonstrated significant antioxidant potential, with CME demonstrating greater DPPH radical scavenging activity, whereas FCME excelled in ABTS radical scavenging. In the animal model, CME and FCME significantly reduced body weight, plasma insulin levels, insulin resistance, and accumulation of fat compared to the obese control group. Moreover, plasma biochemical analysis indicated that both extracts enhanced lipid profiles by reducing cholesterol, triglycerides, and LDL-cholesterol levels, while elevating HDL-cholesterol. Histological analysis revealed decreased hepatic fat accumulation, especially when extracts were concurrently treated with metformin. The research indicates that CME and FCME, especially in conjunction with metformin, have potential anti-obesity and anti-insulin resistance benefits attributed to their abundant polyphenolic content and antioxidant characteristics. This indicates that cha-miang may serve as an effective option for the management of obesity and metabolic diseases.
肥胖是一个主要的全球健康问题，表现为脂肪组织和体重的积累，导致非传染性疾病（NCDs）的发病率更高。变种，被称为茶缅，含有儿茶素及其衍生物，据报道这些成分会影响一些与健康相关的问题，如抗癌、抗炎、抗高血脂和预防心血管疾病。该研究旨在研究新鲜茶缅提取物（CME）和发酵茶缅提取物（FCME）的抗肥胖和胰岛素抵抗作用，并研究CME和FCME对高脂饮食诱导的肥胖大鼠的抗肥胖和抗糖尿病作用。提取物表现出显著的抗氧化潜力，CME表现出更强的DPPH自由基清除活性，而FCME在ABTS自由基清除方面表现出色。在动物模型中，与肥胖对照组相比，CME和FCME显著降低了体重、血浆胰岛素水平、胰岛素抵抗和脂肪积累。此外，血浆生化分析表明，两种提取物通过降低胆固醇、甘油三酯和低密度脂蛋白胆固醇水平，同时提高高密度脂蛋白胆固醇水平，改善了血脂状况。组织学分析显示肝脏脂肪积累减少，特别是当提取物与二甲双胍同时处理时。该研究表明，CME和FCME，特别是与二甲双胍联合使用时，由于其丰富的多酚含量和抗氧化特性，具有潜在的抗肥胖和抗胰岛素抵抗益处。这表明茶缅可能是管理肥胖和代谢疾病的有效选择。
